Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must give a written, signed and dated informed consent.~2. Men or women at least 18 years of age at time of screening.~3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Baseline.~4. Moderate to severe psoriasis as defined at Baseline by:~   * PASI score of 12 or greater, and~  * IGA mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and~  * Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.~5. Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by~   * topical treatment and/or,~  * phototherapy and/or,~  * previous systemic therapy.~Exclusion Criteria:~1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Baseline.~2. Drug-induced psoriasis.~3. Ongoing use of prohibited treatments.~4. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.~5. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.~6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150mg (Type: EXPERIMENTAL): Secukinumab 150mg s.c.
- Secukinumab 300mg (Type: EXPERIMENTAL): Secukinumab 300mg s.c.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to secukinumab s.c

Based on this trial design, predict the completion outcome and termination type (if applicable).